Evidence map›Paper›PMID 39829948›Full record

ArticleChemical engineering journal (Lausanne, Switzerland : 1996)2025

Self-Assembly Nanomedicine Initiating Cancer-Immunity Cycle with Cascade Reactions for Boosted Immunotherapy.

Yajing Guo, Bingyuan Liu, Lixin Yin, Yang Zhou, Ye Wu, Hua Liu, Luyun Tu, Hongxia Huang, Yi Ling, Nicole F Steinmetz and 2 more

Abstract read
In one paragraph

Article in Chemical engineering journal (Lausanne, Switzerland : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Temperature-responsive polymers for bioanalytical systems.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Analytical sensing based on electrochemiluminescence.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026
    Article
  9. Article
  10. Nanozyme-based therapies for inflammatory immune disorders: opportunities and challenges.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Molecular engineering of multifunctional benzothiazole-sulfonamide hybrids: from synthesis to optoelectronic applications.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025
    Article
  15. Article
  16. Article
  17. Medium-Entropy Engineering Enhances Na⁺/Electron Transport in NaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yajing GuoSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Bingyuan LiuSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Lixin YinSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Yang ZhouSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Ye WuSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Hua LiuSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Luyun TuSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Hongxia HuangSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Yi LingSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Center for Nano-ImmunoEngineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California, San Diego, La Jolla, CA 92093, USA.
Sheng HongSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Hui CaiSchool of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
NCI NIH HHS R01 CA224605
6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) therapy has been extensively integrated into cancer clinical management. However, its overall response rate is limited due to the stagnating cancer-immunity cycle (CIC) caused by the immunosuppressive tumor microenvironment (TME). Here, a multi-pronged nanomedicine, defined as LCCS, was constructed by the self-assembly of lactate oxidase, catalase, chlorin e6, and sorafenib. Through cascade reactions, LCCS effectively reprogrammed the TME and re-initiated the CIC by depleting lactate, alleviating hypoxia, inducing immunogenic cell death, and normalizing tumor vessels. Immunological analyses indicated that treatment with LCCS decreased the infiltration of immunosuppressive cells while increasing the recruitment of immune effector cells in tumors. Leveraging the effective operation of the CIC, LCCS improved the efficacy of ICB therapy to inhibit breast cancer, and effectively induced the elimination of colorectal cancer and long-term immune memory. Therefore, multifunctional nanomedicines targeting CIC hold great potential for applications in cancer immunotherapy.

Indexed as

cancer-immunity cycleimmunotherapyphotodynamic therapyself-assemblytumor microenvironment

Identifiers

PMID39829948
PMCPMC11737515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.